Abstract
We investigated the prognostic significance of mutation to the TP53 tumor suppressor gene in a series of 908 breast cancer patients treated with or without adjuvant therapies. The frequency of TP53 mutation detected by single strand conformation polymorphism (SSCP) was 19.4% (176/908) in the overall tumor series. In multivariate analysis, TP53 mutation was independently associated with worse survival in the overall (HR=2.1, 95% CI [1.5–3.1], P<0.0001), non-adjuvant treated (HR=2.2, 95% CI [1.2–4.2], P=0.017) and adjuvant treated (HR=2.0, 95% CI [1.3–3.1], P=0.0009) patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hortobagyi GN, Hung MC, Buzdar AU: Recent developments in breast cancer therapy. Semin Oncol 26: 11-20, 1999
Clarke M, Collins R, Davies C, Godwin J, Gray R, Peto R: Tamoxifen for early breast cancer-an overview of the randomised trials. Lancet 351: 1451-1467, 1998
Ravaioli A, Bagli L, Zucchini A, Monti F: Prognosis and prediction of response in breast cancer: the current role of the main biological markers. Cell Prolif 31: 113-126, 1998
Pharoah PDP, Day NE, Caldas C: Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. Br J Cancer 80: 1968-1973, 1999
Faille A, Decremoux P, Extra JM, Linares G, Espie M, Bourstyn E, Derocquancourt A, Giacchetti S, Marty M, Calvo F: P53 mutations and overexpression in locally advanced breast cancers. Br J Cancer 69: 1145-1150, 1994
Aas T, Borresen AL, Geisler S, Smithsorensen B, Johnsen H, Varhaug JE, Akslen LA, Lonning PE: Specific P53 mutations are associated with de novo resistance to doxorubic in in breast cancer patients. Nat Med 2: 811-814, 1996
Chappuis PO, Estreicher A, Dieterich B, Bonnefoi H, Otter M, Sappino AP, Iggo R: Prognostic significance of p53 mutation in breast cancer: frequent detection of non-missense mutations by yeast functional assay. Int J Cancer 84: 587-593, 1999
Blaszyk H, Hartmann A, Cunningham JM, Schaid D, Wold LE, Kovach JS, Sommer SS: A prospective trial of midwest breast cancer patients: a p53 gene mutation is the most important predictor of adverse outcome. Int J Cancer 89: 32-38, 2000
Chevillard S, Lebeau J, Pouillart P, Detoma C, Beldjord C, Assela in B, Klijanienko J, Fourquet A, Magdelenat H, Vielh P: Biological and clinical significance of concurrent p53 gene alterations, MDR1 gene expression, and S-phase fraction analyses in breast cancer patients treated with primary chemotherapy or radiotherapy. Clin Cancer Res 3: 2471-2478, 1997
Bergh J, Norberg T, Sjogren S, Lindgren A, Holmberg L: Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1: 1029-1034, 1995
Kucera E, Speiser P, Gnant M, Szabo L, Samonigg H, Hausmaninger H, Mittlbock M, Fridrik M, Seifert M, Kubista E, Reiner A, Zeillinger R, Jakesz R: Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node-and steroid receptor positive breast cancer patients. Eur J Cancer 35: 398-405, 1999
Kandioler-Eckersberger D, Ludwig C, Rudas M, Kappel S, Janschek E, Wenzel C, Schlagbauer-Wadl H, Mittlbock M, Gnant M, Steger G, Jakesz R: TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res 6: 50-56, 2000
Berns EMJJ, Foekens JA, Vossen R, Look MP, Devilee P, Henzen-Logmans SC, van Staveren IL, van Putten WLJ, Inganas M, Meijer-van Gelder ME, Cornelisse C, Claassen CJC, Portengen H, Bakker B, Klijn JGM: Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res 60: 2155-2162, 2000
Soong R, Iacopetta BJ: A rapid and nonisotopic method for the screening and sequencing of P53 gene mutations in formalin-fixed, paraffin-embedded tumors. Mod Pathol 10: 252-258, 1997
Iacopetta B, Elsaleh H, Grieu F, Joseph D, Sterrett G, Robbins P: Routine analysis of p53 mutation in clinical breast tumor specimens using fluorescence-based polymerase chain reaction and single strand conformation polymorphism. Diagn Mol Pathol 9: 20-25, 2000
Seshadri R, Leong ASY, McCaul K, Firgaira FA, Setlur V, Horsfall DJ: Relationship between P53 gene abnormalities and other tumor characteristics in breast-cancer prognosis. Int J Cancer 69: 135-141, 1996
Soong R, Iacopetta BJ, Harvey JM, Sterrett GF, Dawkins HJ, Hahnel R, Robbins P: D. Detection of p53 gene mutation by rapid PCR-SSCP and its association with poor survival in breast cancer. Int J Cancer 74: 642-647, 1997
Powell B, Soong R, Iacopetta B, Seshadri R, Smith DR: Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer. Clin Cancer Res 6: 443-451, 2000
Hamilton A, Piccart M: The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2. Ann Oncol 11: 647-663, 2000
Jansson T, Inganas M, Sjogren S, Norberg T, Lindgren A, Holmberg L, Bergh J: p53 status predicts survival in breast cancer patients treated with or without postoperative radiotherapy: a novel hypothesis based on clinical findings. J Clin Oncol 13: 2745-2751, 1995
Lavarino C, Pilotti S, Oggionni M, Gatti L, Perego P, Bresciani G, Pierotti MA, Scambia G, Ferrandina G, Fagotti A, Mangioni C, Lucchini V, Vecchione F, Bolis G, Scarfone G, Zunino F: p53 gene status and response to platinum/paclitaxelbased chemotherapy in advanced ovarian carcinoma. J Clin Oncol 18: 3936-3945, 2000
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Powell, B., Bydder, S., Grieu, F. et al. Prognostic value of TP53 gene mutation in adjuvant treated breast cancer patients. Breast Cancer Res Treat 69, 65–68 (2001). https://doi.org/10.1023/A:1012233509663
Issue Date:
DOI: https://doi.org/10.1023/A:1012233509663